Anbio Biotechnology Class A (NNNN) Income Statement
NNNN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNNNN revenue and net income
Where NNNN's revenue goes
2025Each bar shows an amount and its share of revenue. NNNN kept 74.1% of revenue as net income.
NNNN profit margins
NNNN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +5.6% | −28.4% | — | — |
| Gross profit | +28.2% | −15.6% | — | — |
| Operating income | +189.1% | −17.3% | — | — |
| Net income | +169.9% | −13.8% | — | — |
| EPS (diluted) | +150.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NNNN quarterly EPS vs estimates
Anbio Biotechnology beat the analyst EPS estimate in 1 of the last 2 quarters.
NNNN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $8.6M | $8.2M | $6.7M | $23.5M | $4.4M |
| Cost of revenue | $1.1M | $2.3M | $3.4M | $11.0M | $1.9M |
| Gross profit | $7.5M | $5.9M | $3.4M | $12.6M | $2.5M |
| Research & development | $201,305 | $454,227 | $134,700 | $200,000 | $0 |
| Sales, general & admin | $1.6M | $3.4M | $1.3M | $2.2M | $86,095 |
| Total operating expenses | $1.8M | $3.9M | $1.4M | $2.4M | $86,095 |
| Operating income | $5.8M | $2.0M | $2.0M | $10.2M | $2.5M |
| Interest income | $142,023 | $337,511 | $165,336 | $42,245 | $0 |
| Interest expense | — | $0 | $0 | $7,999 | $0 |
| Income before taxes | $6.4M | $2.4M | $2.3M | $10.0M | $2.5M |
| Net income | $6.4M | $2.4M | $2.3M | $10.0M | $2.5M |
| EBITDA | $5.8M | $2.0M | $2.3M | $10.0M | $2.5M |
| EPS (diluted) | $0.15 | $0.06 | $0.05 | — | — |
| Gross margin | 87.2% | 71.9% | 50.1% | 53.4% | 57.4% |
| Operating margin | 66.7% | 24.4% | 29.2% | 43.3% | 55.5% |
| Net margin | 74.1% | 29.0% | 33.6% | 42.5% | 57.3% |
| Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Jun '24 | Dec '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $2.0M | $5.0M | $0 | $2.5M | $6.3M | $4.0M | $3.3M |
| Cost of revenue | $876,722 | $375,871 | $384,382 | $175,970 | $390,512 | $2.1M | $2.3M | $1.4M |
| Gross profit | $3.9M | $1.7M | $4.6M | −$2.6M | $2.1M | $4.2M | $1.7M | $1.9M |
| Research & development | $81,637 | $35,000 | $143,409 | $65,653 | $353,467 | $138,025 | $145,696 | — |
| Total operating expenses | $1.1M | $454,997 | $945,209 | −$686,064 | $3.9M | $337,502 | $1.1M | $406,055 |
| Operating income | $2.8M | $1.2M | $3.7M | −$1.9M | −$1.7M | $3.9M | $583,740 | $1.5M |
| Income before taxes | $3.0M | $1.3M | $4.1M | −$2.1M | −$1.3M | $3.9M | $792,932 | $1.6M |
| Net income | $3.0M | $1.3M | $4.1M | −$2.1M | −$1.3M | $3.9M | $792,932 | $1.6M |
| EBITDA | $2.8M | — | $3.7M | — | −$1.3M | $3.9M | $796,474 | $1.5M |
| EPS (diluted) | — | $0.09 | — | −$0.03 | — | — | — | — |
| Gross margin | 81.5% | 81.5% | 92.3% | — | 84.6% | 66.9% | 42.8% | 58.7% |
| Operating margin | 59.1% | 59.1% | 73.4% | — | −68.6% | 61.5% | 14.8% | 46.5% |
| Net margin | 64.1% | 64.1% | 82.8% | — | −52.4% | 61.5% | 20.1% | 49.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NNNN's financial statements (latest annual report filed April 7, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NNNN financial results
In fiscal year 2025 (ended December 31, 2025), Anbio Biotechnology reported revenue of $8.6 million, up 5.6% from the year before. It had net income of $6.4 million (up 169.9%), a net profit margin of 74.1%. Diluted earnings per share came to $0.15.
See the NNNN stock overview for the latest quote and news, or the NNNN chart for price history and technical indicators.
NNNN income statement FAQ
What is Anbio Biotechnology's annual revenue?
Anbio Biotechnology reported total revenue of $8.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 5.6% from $8.2 million the previous year.
Is Anbio Biotechnology profitable?
Yes. Anbio Biotechnology reported net income of $6.4 million in fiscal 2025, a net profit margin of 74.1%; its operating margin was 66.7%.
What is Anbio Biotechnology's gross margin?
Anbio Biotechnology's gross margin was 87.2% in fiscal 2025: for every $100 of revenue, Anbio Biotechnology kept $87 after the direct cost of its products and services.
How much does Anbio Biotechnology spend on research and development?
Anbio Biotechnology spent $0.2 million on research and development in fiscal 2025, 2.3% of revenue.
What are Anbio Biotechnology's earnings per share?
Anbio Biotechnology earned $0.15 per diluted share in fiscal 2025, compared with $0.06 a year earlier.
When does Anbio Biotechnology's fiscal year end?
Anbio Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 7, 2026.